Cushing's Disease in a High-Risk Surgical Candidate: Operate Now or Bridge With Medical Therapy
A single patient with a technically curable pituitary tumor whose own hypercortisolism has made the surgery to remove it dangerously risky, forcing the team to decide how long to wait, not just whether to.
Rosalind K., a 51-year-old woman, ran her own catering business until eight months ago, when what she describes as "just getting older and heavier" turned out to be Cushing's disease — a 6 mm ACTH-secreting pituitary microadenoma, confirmed by inferior petrosal sinus sampling after her endocrinologist noticed the pattern beneath the weight gain: new-onset diabetes with an A1c of 11%, blood pressure that stopped responding to three agents, and, three weeks ago, an unprovoked deep vein thrombosis in her left calf. An echocardiogram obtained during that admission found an ejection fraction of 25%, new and almost certainly downstream of years of unrecognized hypercortisolism rather than an unrelated cardiac process. Transsphenoidal surgery is the guideline first-line treatment for Cushing's disease and, in her case, technically straightforward — a small, well-localized microadenoma is exactly the tumor this operation cures most reliably. The complication is that anesthesiology's preoperative evaluation flagged her as a high-risk surgical candidate on the strength of the EF alone, before her diabetes and clotting risk are even weighed in.
Whether to operate now, delay for medical pretreatment, or set some other threshold first is genuinely unsettled territory. The ERCUSYN European registry found that patients who received preoperative medical treatment before Cushing's surgery were, on average, sicker at diagnosis than those who went straight to surgery — and that by six months, morbidity and remission rates were no different between the two groups, though early postoperative cortisol assessment was harder to interpret in the pretreated group. That finding cuts against a clean answer either way: it does not show medical pretreatment clearly helps, but it does show the sickest patients are the ones already being routed toward it in real practice, which is exactly the population Rosalind's EF places her in.
Multidisciplinary planning, endocrine surgery and cardiology
Her tumor is exactly the kind we cure reliably — small, well-localized, confirmed on IPSS. Every week we wait is another week of active hypercortisolism doing more damage to the heart and clotting system we're worried about. I don't think delay is actually the safer option here; it's the same risk, extended.
I agree the tumor itself isn't the hard part. But an EF of 25% under general anesthesia today is a real, immediate risk that a favorable tumor doesn't offset. The 2021 Pituitary Society consensus update on Cushing's disease (Fleseriu et al.) explicitly recognizes preoperative cortisol-lowering in severe or high-operative-risk disease, and there is real published precedent for using a steroidogenesis inhibitor that way — osilodrostat has been used this way before adrenalectomy in adrenal Cushing's syndrome specifically to reduce operative risk. I don't think the ERCUSYN registry finding — that pretreated patients did no better or worse by six months — argues against trying; it mostly tells us those patients started sicker, which is exactly Rosalind's situation.
I take the "delay extends exposure" point seriously — I'm not proposing open-ended medical therapy, just enough time to see if her heart can tolerate the operation she needs.
Then let's make "enough time" a real number, not an open door. Eight weeks of cortisol-lowering therapy, with a repeat echocardiogram and A1c at the end: if her EF has climbed meaningfully and her glucose is controlled, she goes to surgery then, at genuinely lower anesthesia risk. If it hasn't moved, we're not chasing an indefinite medical trial — we reconvene and decide whether to accept today's risk profile or pursue an alternative. Either way, the decision doesn't drift past eight weeks.
Agreed: an eight-week course of osilodrostat targeting cortisol normalization, with a repeat echocardiogram and A1c at the end of that window to decide surgical timing against pre-set thresholds.
Not agreed: what happens if her EF improves only partially — meaningfully better but still below what anesthesiology would call low-risk. The neurosurgeon would proceed regardless at that point, arguing a partial improvement plus a technically favorable tumor outweighs further delay; the cardiologist wants a second, shorter reassessment window before accepting anything short of the original target.